Photo from wikipedia
Hereditary transthyretin-mediated (hATTR) amyloidosis is a progressive, life-threatening disease. The majority of patients develop a mixed phenotype of polyneuropathy and cardiomyopathy. Patisiran is approved in certain countries globally for the… Click to show full abstract
Hereditary transthyretin-mediated (hATTR) amyloidosis is a progressive, life-threatening disease. The majority of patients develop a mixed phenotype of polyneuropathy and cardiomyopathy. Patisiran is approved in certain countries globally for the treatment of hATTR amyloidosis with polyneuropathy.
Keywords:
transthyretin mediated;
amyloidosis polyneuropathy;
amyloidosis;
hereditary transthyretin
Journal Title: Journal of the American College of Cardiology
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of the American College of Cardiology
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!